These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis. Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722 [TBL] [Abstract][Full Text] [Related]
15. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance. Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916 [TBL] [Abstract][Full Text] [Related]
16. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611 [TBL] [Abstract][Full Text] [Related]
17. Dual targeting of BCL-2 and MCL-1 in the presence of BAX breaks venetoclax resistance in human small cell lung cancer. Valko Z; Megyesfalvi Z; Schwendenwein A; Lang C; Paku S; Barany N; Ferencz B; Horvath-Rozsas A; Kovacs I; Schlegl E; Pozonec V; Boettiger K; Rezeli M; Marko-Varga G; Renyi-Vamos F; Hoda MA; Klikovits T; Hoetzenecker K; Grusch M; Laszlo V; Dome B; Schelch K Br J Cancer; 2023 May; 128(10):1850-1861. PubMed ID: 36918717 [TBL] [Abstract][Full Text] [Related]
18. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442 [TBL] [Abstract][Full Text] [Related]
19. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284 [TBL] [Abstract][Full Text] [Related]